Heat shock proteins, cell survival and drug resistance: The mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy

被引:71
作者
Landriscina, Matteo [2 ]
Amoroso, Maria Rosaria [1 ,3 ]
Piscazzi, Annamaria [2 ]
Esposito, Franca [1 ,3 ]
机构
[1] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy
[2] Univ Foggia, Dept Med Sci, Clin Oncol Unit, I-71100 Foggia, Italy
[3] CEINGE Biotecnol Avanzate, Naples, Italy
关键词
Ovarian carcinoma; Heat shock proteins; TRAP1; Drug resistance; Apoptosis; TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; EGCG INHIBITS GROWTH; PHASE-III TRIAL; IN-VITRO; BREAST-CANCER; HSP90; INHIBITOR; GENE-EXPRESSION; ANTITUMOR-ACTIVITY; INTERGROUP TRIAL; SINGLE-AGENT;
D O I
10.1016/j.ygyno.2009.10.078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Protein homeostasis is a highly complex network of molecular interactions governing the health and life span of the organism. Molecular chaperones, mainly heat shock proteins (HSP) and other stress-inducible proteins abundantly expressed in multiple compartments of the cell, are major modulators of protein homeostasis. TRAM is a mitochondrial HSP involved in protection against oxidant-induced DNA damage and apoptosis. It was recently described as a component of a mitochondrial pathway selectively up-regulated in tumor cells which antagonizes the proapoptotic activity of cyclophilin D, a mitochondrial permeability transition pore regulator, and is responsible for the maintenance of mitochondrial integrity, thus favoring cell survival. Interestingly, novel TRAP1 antagonists cause sudden collapse of mitochondrial function and selective tumor cell death, suggesting that this pathway may represent a novel molecular target to improve anticancer therapy. Preliminary data suggest that TRAP1 may be a valuable biomarker in ovarian cancers: in fact, TRAP1 levels are significantly higher in cisplatin-resistant ovarian tumors and ovarian carcinoma cell lines. Conclusions. While major advances have been made in understanding the genetics and molecular biology of cancer, given the considerable heterogeneity of ovarian cancer, the introduction of novel targeted therapies and the consequent selection of treatments based on the molecular profile of each tumor may have a major impact on the management of this malignancy and might contribute to building a new era of personalized medicine. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 80 条
[1]   Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance [J].
Alvero, Ayesha B. ;
Chen, Rui ;
Fu, Han-Hsuan ;
Montagna, Michele ;
Schwartz, Peter E. ;
Rutherford, Thomas ;
Silasi, Dan-Arin ;
Steffensen, Karina D. ;
Waldstrom, Marianne ;
Visintin, Irene ;
Mor, Gil .
CELL CYCLE, 2009, 8 (01) :158-166
[2]  
Arrigo Andre-Patrick, 2002, Prog Mol Subcell Biol, V28, P185
[3]   An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models [J].
Banerji, Udai ;
Sain, Nivedita ;
Sharp, Swee Y. ;
Valenti, Melanie ;
Asad, Yasmin ;
Ruddle, Ruth ;
Raynaud, Florence ;
Walton, Michael ;
Eccles, Suzanne A. ;
Judson, Ian ;
Jackman, Ann L. ;
Workman, Paul .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) :769-778
[4]   The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future [J].
Banerji, Udai ;
Judson, Ian ;
Workman, Paul .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :385-390
[5]   The biology of ovarian cancer: new opportunities for translation [J].
Bast, Robert C., Jr. ;
Hennessy, Bryan ;
Mills, Gordon B. .
NATURE REVIEWS CANCER, 2009, 9 (06) :415-428
[6]   Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways [J].
Beere, HM .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2633-2639
[7]  
Beliakoff J, 2003, CLIN CANCER RES, V9, P4961
[8]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[9]   Targeting Heat Shock Protein 90 with Non-Quinone Inhibitors: A Novel Chemotherapeutic Approach in Human Hepatocellular Carcinoma [J].
Breinig, Marco ;
Caldas-Lopes, Eloisi ;
Goeppert, Benjamin ;
Malz, Mona ;
Rieker, Ralf ;
Bergmann, Frank ;
Schirmacher, Peter ;
Mayer, Matthias ;
Chiosis, Gabriela ;
Kern, Michael Andre .
HEPATOLOGY, 2009, 50 (01) :102-112
[10]   Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models [J].
Caldas-Lopes, Eloisi ;
Cerchietti, Leandro ;
Ahn, James H. ;
Clement, Cristina C. ;
Robles, Ana I. ;
Rodina, Anna ;
Moulick, Kamalika ;
Taldone, Tony ;
Gozman, Alexander ;
Guo, Yunke ;
Wu, Nian ;
de Stanchina, Elisa ;
White, Julie ;
Gross, Steven S. ;
Ma, Yuliang ;
Varticovski, Lyuba ;
Melnick, Ari ;
Chiosis, Gabriela .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (20) :8368-8373